(Q33776134)

29 July 2017

1 reference

title

Cell-based vaccines for the stimulation of immunity to metastatic cancers (English)

1 reference

29 July 2017

Ostrand-Rosenberg S

1

1 reference

29 July 2017

Pulaski BA

2

1 reference

29 July 2017

Clements VK

3

1 reference

29 July 2017

Qi L

4

1 reference

29 July 2017

Pipeling MR

5

1 reference

29 July 2017

Hanyok LA

6

1 reference

29 July 2017

1 August 1999

1 reference

29 July 2017

Immunological Reviews

1 reference

29 July 2017

170

1 reference

29 July 2017

101-114

1 reference

T cell defined tumor antigens

29 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Helper activity is required for the in vivo generation of cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Tumor immunotherapy: the tumor cell as an antigen-presenting cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Specific carcinoembryonic antigens of the human digestive system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Beta-catenin as oncogene: the smoking gun.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Stabilization of beta-catenin by genetic defects in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Oncogenic proteins as tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

The new vaccines: building viruses that elicit antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Mechanisms of antigen uptake for presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Capture and processing of exogenous antigens for presentation on MHC molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Tumor antigen presentation: changing the rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Antigen processing and presentation by the class I major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Mechanisms of MHC class I--restricted antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Regulation of MHC class II genes: lessons from a disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Class II transactivator regulates the expression of multiple genes involved in antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Invariant chain structure and MHC class II function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Mediation by HLA-DM of dissociation of peptides from HLA-DR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

Peptide-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01332.X

10.1111/J.1600-065X.1999.TB01332.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference